, Volume 75, Issue 1, pp 91–100 | Cite as

Delamanid: A Review of Its Use in Patients with Multidrug-Resistant Tuberculosis

  • Hannah A. BlairEmail author
  • Lesley J. Scott
Adis Drug Evaluation


Delamanid (Deltyba®), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB) drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. It is approved in several countries, including Japan and those of the EU, for use as part of an appropriate combination regimen in adults with multidrug-resistant tuberculosis (MDR-TB) when an effective treatment regimen cannot otherwise be composed due to resistance or tolerability. In a robust phase II trial in adult patients with MDR-TB, oral delamanid 100 mg twice daily for 2 months plus an optimized background regimen improved sputum culture conversion rates to a significantly greater extent than placebo. In a 6-month extension study, long-term (≤8 months) treatment with delamanid was associated with a higher incidence of favourable outcomes (i.e. cured or completed all treatment) than short-term (≤2 months) treatment, with an accompanying reduction inunfavourable outcomes as defined by the WHO (i.e. pre-specified proportion of TB-positive sputum cultures, death or treatment discontinuation for ≥2 months without medical approval). Delamanid was not associated with clinically relevant drug-drug interactions, including with antiretroviral drugs and those commonly used in treating TB. Delamanid was generally well tolerated in patients with MDR-TB, with gastrointestinal adverse events and insomnia reported most commonly. Although the incidence of QT interval prolongation was higher with delamanid-based therapy, it was not associated with clinical symptoms such as syncope and arrhythmia. In conclusion, delamanid is a useful addition to the treatment options currently available for patients with MDR-TB.


Isoniazid Ethambutol Optimize Background Regimen Sputum Culture Conversion Sputum Culture Negativity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit. Hannah Blair and Lesley Scott are salaried employees of Adis/Springer.


  1. 1.
    World Health Organization. Global tuberculosis report 2013. 2013. Accessed 7 Nov 2014.
  2. 2.
    Lange C, Abubakar I, Alffenaar JW, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014;44(1):23–63.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis. 2014;14(4):327–40.PubMedCrossRefGoogle Scholar
  4. 4.
    Brigden G, Nyang’wa B-T, du Cros P, et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ. 2014;92(1):68–74.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    European Medicines Agency. Delamanid assessment report. 2013. Accessed 7 Nov 2014.
  6. 6.
    Matteelli A, Roggi A, Carvalho ACC. Extensively drug-resistant tuberculosis: epidemiology and management. Clin Epidemiol. 2014;6(1):111–8.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Dooley KE, Nuermberger EL, Diacon AH. Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS. 2013;8(6):579–85.PubMedCrossRefGoogle Scholar
  8. 8.
    Kwon Y-S, Jeong B-H, Koh W-J. Tuberculosis: clinical trials and new drug regimens. Curr Opin Pulm Med. 2014;20(3):280–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Reviriego C. Delamanid antimycobacterial agent treatment of tuberculosis. Drug Future. 2013;38(1):7–12.CrossRefGoogle Scholar
  10. 10.
    Field SK. Safety and efficacy of delamanid in the treatment of multidrug-resistant tuberculosis (MDR-TB). Clin Med Insights Ther. 2013;5:137–49.CrossRefGoogle Scholar
  11. 11.
    European Medicines Agency. Delamanid (Deltyba): summary of product characteristics. 2014. Accessed 7 Nov 2014.
  12. 12.
    Diacon AH, Von Groote-Bidlingmaier F, Donald PR. Delamanid, a new 6-nitro-2,3-dihydroimidazo[2,1-b]oxazole for the management of tuberculosis resistant to at least isoniazid and rifampicin. Expert Opin Orphan Drugs. 2014;2(1):87–94.CrossRefGoogle Scholar
  13. 13.
    Hurdle JG, Lee RB, Budha NR, et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother. 2008;62(5):1037–45.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3(11):e466.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    van den Boogaard J, Kibiki GS, Kisanga ER, et al. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother. 2009;53(3):849–62.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Saliu OY, Crismale C, Schwander SK, et al. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis. J Antimicrob Chemother. 2007;60(5):994–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2011;15(7):949–54.PubMedCrossRefGoogle Scholar
  18. 18.
    Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151–60.PubMedCrossRefGoogle Scholar
  19. 19.
    Otsuka Pharmaceutical Co. Ltd. Deltyba (delamanid): Japanese prescribing information. Tokyo: Otsuka Pharmaceutical Co., Ltd.; 2014.Google Scholar
  20. 20.
    Paccaly A, Petersen C, Patil S, et al. Absence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ ritonavir in healthy subjects [abstract no. WEPE043]. In: 19th international AIDS conference. Washington, DC; 22–27 Jul 2012.Google Scholar
  21. 21.
    Petersen C, Paccaly A, Kim J, et al. Delamanid, a new drug for multi-drug resistant tuberculosis (MDR-TB), and efavirenz do not show clinically relevant drug interactions in healthy subjects [abstract no. A-1255]. In: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Fransisco; 9–12 Sep 2012.Google Scholar
  22. 22.
    Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013;41(6):1393–400.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Zhang Q, Liu Y, Tang S, et al. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China. Cell Biochem Biophys. 2013;67(3):957–63.PubMedCrossRefGoogle Scholar
  24. 24.
    Medecins Sans Frontieres. DR-TB drugs under the microscope: sources and prices for drug resistant TB medications. 2013. Accessed 7 Nov 2014.
  25. 25.
    Otsuka Pharmaceutical Development & Commercialization Inc. Safety and efficacy trial of delamanid for 6 months in patients with multidrug resistant tuberculosis [ identifier NCT01424670]. US National Institutes of Health, 2011. Accessed 7 Nov 2014.

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations